Skip to main content
World Journal of Clinical Cases logoLink to World Journal of Clinical Cases
. 2019 Sep 6;7(17):2463–2476. doi: 10.12998/wjcc.v7.i17.2463

Multiplex gene expression profile in inflamed mucosa of patients with Crohn’s disease ileal localization: A pilot study

Francesco Giudici 1, Letizia Lombardelli 2, Edda Russo 3, Tiziana Cavalli 4, Daniela Zambonin 5, Federica Logiodice 6, Ornela Kullolli 7, Lamberto Giusti 8, Tatiana Bargellini 9, Marilena Fazi 10, Livia Biancone 11, Stefano Scaringi 12, Ann Maria Clemente 13, Eloisa Perissi 14, Giovanni Delfino 15, Maria G Torcia 16, Ferdinando Ficari 17, Francesco Tonelli 18, Marie-Pierre Piccinni, Cecilia Malentacchi 19
PMCID: PMC6745337  PMID: 31559282

Abstract

BACKGROUND

Crohn’s disease (CD) is a complex disorder resulting from the interaction of genetic, environmental, and microbial factors. The pathogenic process may potentially affect any segment of the gastrointestinal tract, but a selective location in the terminal ileum was reported in 50% of patients.

AIM

To characterize clinical sub-phenotypes (colonic and/or ileal) within the same disease, in order to identify new therapeutic targets.

METHODS

14 consecutive patients undergoing surgery for ileal CD were recruited for this study. Peripheral blood samples from each patient were collected and the main polymorphisms of the gene Card15/Nod2 (R702W, G908R, and 1007fs) were analyzed in each sample. In addition, tissue samples were taken from both the tract affected by CD and from the apparently healthy and disease-free margins (internal controls). We used a multiplex gene assay in specimens obtained from patients with ileal localization of CD to evaluate the simultaneous expression of 24 genes involved in the pathogenesis of the disease. We also processed surgery gut samples with routine light microscopy (LM) and transmission electron microscopy (TEM) techniques to evaluate their structural and ultrastructural features.

RESULTS

We found a significant increase of Th17 (IL17A and IL17F, IL 23R and CCR6) and Th1 (IFN-γ) gene expression in inflamed mucosa compared to non-inflamed sites of 14 CD patients. DEFB4 and HAMP, two genes coding for antimicrobial peptides, were also strongly activated in inflamed ileal mucosa, suggesting the overwhelming stimulation of epithelial cells by commensal microbiota. IFN-γ and CCR6 were more expressed in inflamed mucosa of CD patients with ileal localization compared with patients with colonic localization suggesting a more aggressive inflammation process in this site. Morphological analysis of the epithelial lining of Lieberkün crypts disclosed enhanced release activity from goblet mucocytes, whereas the lamina propria contained numerous cells pertaining to various lines.

CONCLUSION

We observed that the expression of ileal genes related to Th1 and Th17 activity is strongly activated as well as the expression of genes involved in microbiota regulation.

Keywords: Crohn’s disease, Ileum, Colon, Messenger ribonucleic acid, Th1/Th17, Microbiota, Inflammation


Core tip: Multiplex Gene Assay in specimens obtained from patients with ileal localization of Crohn’s disease (CD) allowed the simultaneous analysis of messenger ribonucleic acid levels for 24 genes, known to be involved in the inflammation processes of CD pathogenesis. The result showed that the expression of genes related to Th1 and Th17 immune response is strongly activated as well as the expression of genes deputized to interact with the commensal microbiota, such as DEFB4 and HAMP, which code for antimicrobial peptides.

INTRODUCTION

The pathogenesis of Crohn’s disease (CD), one of the major inflammatory bowel diseases (IBD) together with ulcerative colitis (UC), has been extensively investigated. It is generally accepted that both genetic and environmental factors contribute to the etiology of the disease. In CD patients, strong associations between genes involved in maintaining intestinal barrier function, epithelial anti- microbial defence, innate immune regulation, reactive oxygen species (ROS) generation, autophagy, and metabolic pathways have been identified[1,2].

Environmental risk factors involved in the progression of the disease include smoking, low-fiber and high-carbohydrate diet, gut microbiota (GM) alteration, and treatments with antibiotics or non-steroidal anti-inflammatory drugs[3].

CD is characterized by a transmural inflammation which can potentially affect any segment of the gastrointestinal tract[4]. However, recent studies reported a selective location in the terminal ileum in 50% of the patients and location in the colonic district in 20% of the patients. Ileum and colon district were involved in the remaining 30% of the patients. A different clinical course and surgical requirement was reported according to disease’s localization but currently the reasons underlying the differences in the clinical course have not been defined. In addition, the immunological pathways involved in colonic inflammation are different from those involved in ileal inflammation[5].

The mutual interplay between GM and the immune system is involved in the pathogenesis and prognosis of intestinal diseases[6] as the GM is a key modulator of intestinal inflammation[7]. In CD patients, a reduced GM diversity and lower bacterial load in inflamed vs non-inflamed tissues was observed[8]. In addition, several evidences report that the small bowel is responsible for the systemic tolerance towards microbes. A recent study revealed that the ileum harbors a distinctive niche of the GM that differs more from the colonic[9]. This different GM composition could be attributed to the activation of distinctive immunological pathways.

In the present study, we used the multiplex gene assay[10,11] to analyze surgical specimens of CD patients with prevalent ileal localization.

MATERIALS AND METHODS

Patients

14 consecutive patients undergoing surgery for ileal CD aged 15 to 57 and hospitalized at the Surgery Unit of Azienda Ospedaliero-Universitaria Careggi, University of Florence, were recruited (Table 1). CD was diagnosed based on both histological and clinical/endoscopic criteria. Table 1 reports the clinical characteristics of the patients.

Table 1.

Clinical characteristics of patients with ileal Crohn’s disease

Patient Pt1 Pt2 Pt3 Pt4 Pt5 Pt6 Pt7 Pt8 Pt9 Pt10 Pt11 Pt12 Pt13 Pt14
Localization L1 L1 L1 L1 L1 L1 L3 L1 L3 L1 L3-L4 L1 L3 L1
of CDa
Age of CD 57 15 53 55 25 31 39 42 16 24 19 18 46 30
onset (yr)
Surgery / relapse 1st 1st Relapse 1st Relapse Relapse Relapse 1st Relapse Relapse Relapse Relapse Relapse 1st
surgery surgery surgery surgery surgery
Disease behaviorb B2 B2, B3 B2 B3 B2, B4 B2 B3 B2 B2 B2 B2 B2 B3 B2
Therapyc C, F, I, B F, C C No F, C, I C, F, I I, B F, C C, I, F, B C F, C, B F, C, I C, F, B, I F, C, I
Smoking statusd No Cur No No 10月10日 No No 20/30 10月10日 Cur 10月20日 No No No
20/15.5 10
Genotype wt R702 wt hzG881R wt wt wt wt hzG881R R702 No seq No seq wt wt

Localization of Crohn Disease: L1: terminal ileum; L2: colon; L3: ileum colon; L4: upper G (gastrointestinal); Disease behavior: B1: non-stricturing, non-penetrating; B2: stricturing; B3: penetrating; B4: perianal disease. Therapy: M: mesalazine; I: immunosuppressant; B: biologics; C: corticosteroids; Ab: antibiotics. Smoking status: No: non-smoker; Ex: ex-smoker; Cur: current smoker, no. cigs per day / no. yr. MIM: Mendelian inheritance in Man. 1: Transport across epithelia; 2: Immune response; 3: Antimicrobial activity; 4: Different physiological activities.

Peripheral blood samples from each patient were collected in EDTA tubes and genomic DNA was extracted using QIA-AMP DNA Blood Maxi Kit (Qiagen GmbH, Hilden, Germany). The main polymorphisms of the gene Card15/Nod2 (R702W, G908R, and 1007fs) were analysed in each sample[12].

mRNA extraction and multiplex Gene Assay

Tissue samples were taken both from the tract affected by CD and from the apparently healthy and disease-free margins (internal controls). The surgical specimens were opened longitudinally.

All samples were stored in RNA later (Qiagen, Germany) before homogenization. Then each sample was weighed and the appropriate lysis solution was added to a final volume of 150 µL containing 50% Lysis Mixture (Thermo-Fisher, MA, United States) and 1 g/L proteinase. The mixture was agitated for 30 min at 65 °C to lyse the cells. The lysate was stored at -80 °C for later use. We used a microarray panel of 24 genes implicated in CD etiopathogenesis[10]. We evaluated the expression of these genes in both non-inflamed and inflamed ileal biopsies. Table 2 indicates the panel of the examined genes, the number of Mendelian Inheritance in Man (MIM) (used as a reference), accession number and their corresponding encoded product and function. To improve the analysis of the results, the selected genes were divided into four groups according to their biological role: (1) Transport across epithelia: ABCB1, SLC40A1, SLC22A4, SLC22A5, HAMP; (2) Immune response: CCR6, IL-17F, IL-17A, MICA, MYD88, STAT3, IL-23R, JAK2, IFNG, NOD2; (3) Antimicrobial activity: HAMP, CAMP, LRRK2.DEFB4; and (4) Physiological activities: STAT3, ESR1, LRRK2, TNFSF15, CARD14, DLG5 BMP2 ATG16L1.

Table 2.

Panel of the 24 genes investigated

Symbol Complete name Group Accession number mim Gene product function (s) Ref.
HPRT1 Hypoxanthine phosphoribosyltransferase 1 Low expression housekeeping gene M26434 308000 It plays a central role in the generation of purine nucleotides, chosen as a low expression housekeeping gene [39]
ACTB Actin betaprovided High expression housekeeping gene M28424 102630 Is involved in the cell motility, structure, and integrity [40]
SLC40A1 Solute carrier family 40 (iron-regulated transporter), member1 1 AF215636 604653 Exports iron from duodenal epithelial cells [41]
ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), member1 1 M14758 171050 Transports various molecules across extra- and intra-cellular membranes. It belongs to a protein sub-family involved in multidrug resistance [42]
SLC22A5 Solute carrier family 22 (organic cation/carnitine transporter), member 5 1 AF057164 603377 Transports several small organic cations in the liver, kidney, intestine. It is involved in elimination of drugs and environmental toxins [43]
SLC22A4 Solute carrier family 22 (organic cation/ergothioneine transporter), member 4 1 AB007448 604190 Polyspecific transporter of organic cations in the liver, kidney, intestine, and involved in the elimination of these molecules. [44]
CCR6 Chemokine (C-C motif) receptor6 2 U68030 601835 Induces B-lineage maturation and antigen-driven B-cell differentiation [45]
IL17A Interleukin 17A 2 U32659 603149 Produced by Th17-type CD4+ cells. Regulates the activities of NF-kB and mitogen-activated protein kinases [26]
IL17F Interleukin 17F 2 AF384857 606496 Produced by Th17-type CD4+ cells. Stimulates the production of other cytokines, including IL6,IL8.It also inhibits angiogenesis by endothelial [46]
cells.
STAT3 Signal transducer and activator of transcription 3 (acute-phase response factor) 2-4 BC014482 102582 Activates transcription of cell growth and apoptosis’ genes asresponses to inflammation [22,47]
MICA MHC class I polypeptide-related sequence A 2 L14848 600169 Acts as a stress-induced antigen broadly recognized by intestinal intra-epithelial gamma delta T cells. [48,49]
MYD88 Myeloid differentiation primary response gene (88) 2 U84408 602170 Acts as an essential signal transducer in the interleukin-1 and Toll-like receptor signaling [50]
pathways
IL23R Interleukin 23 receptor 2 AF461422 607562 Expressed on Th17 cells. Involvedin the IL23A signaling pathways with the receptor molecule IL12RB1/IL12Rbeta1. [20]
JAK2 Janus kinase 2 2 3717 147796 Is involved in cytokine receptor signaling pathways and is required for responses to gamma interferon [51]
IFNG Interferon, gamma 2 3458 147570 It encodes a cytokine with antiviral,immunoregulatory and anti-tumor properties and activates macrophages [52]
CAMP Cathelicidin antimicrobial peptide 3 BC055089 600474 It is an antimicrobial protein (defensin) [53]
CARD15 Nucleotide-binding oligomerization domain containing 2 2 AF178930 605956 Induces immune response to intracellular bacterial by recognizing the muramyl dipeptide (MDP) [54]
DEFB4 Defensin, beta 4A 3 AJ314835 602215 Acts as an antibiotic peptide locally regulated by inflammation. [55,56]
HAMP Hepcidin antimicrobialpeptide 1/2/3 AF309489 606464 It is involved in iron transport, antimicrobial, defence and inflammatory responses [57,58]
LRRK2 Leucine-rich repeat kinase 2 3/4 AK026776 609007 It is involved in autophagy and implicated in clearance of intracellular bacteria. [59,60]
TNFSF15 Tumor necrosis facto (ligand) superfamily, member 15 4 AF039390 604052 Induces apoptosis in endothelial cells [61]
CARD14 Caspase recruitment domain family, member 14 4 AF322642 607211 Regulates the molecular scaffolding process and activates NF-kappa B [62,63]
ATG16L1 ATG16 autophagy related 16-like 1 4 AK000897 610767 Induces autophagy processes involved in degradation of cell organelles [64]
ESR1 Estrogen receptor 1 4 X03635 133430 Involved in the metabolic pathway of the hormones and in several diseases including osteoporosis [65]
BMP2 Bone morphogenetic protein 2 4 650 112261 Induces bone and cartilage formation [66]
DLG5 Discs, large homolog 5 4 U61843 604090 It encodes for scaffolding molecules involved in cell-cell contact and in the maintenance of epithelial cell integrity. Its products are also involved in the transmission of extracellular signals [67]

MIM: Mendelian Inheritance in Man. 1: Transport across epithelia; 2: Immune response; 3: Antimicrobial activity; 4: Different physiological activities.

The messenger ribonucleic acid (mRNA) expression for CCR6, IL-17A, IL-17F, BMP2, TNFSF15, ABCB1, IL-23R, DEFB4, CARD14, STAT3, SLC40A1, JAK2, SLC22A5, ACTB, ATG16L1, CAMP, DLG5, ESR1,CARD15, MICA, MYD88, SLC22A4, IFN-γ, LRRK2, HAMP, ACTB (high expression housekeeping gene), HPTR1 (low expression housekeeping gene) was measured using the QuantiGene® Plex assay (Thermo-Fisher, MA, United States).

A panel of oligonucleotide capture probes was covalently linked to carboxylated fluorescently encoded beads (Luminex, Bio-Rad, MA, United States). Each probe has a unique sequence of 15 bases. Each sample lysate diluted at 1:1 and 1:2 was mixed with the pooled capture beads in a round-bottom assay well and hybridized for 16 h at 54 °C (final volume in each well was 100 µL). The assay mixture was moved to a MultiScreen® Filter Plate (Millipore, Billerica, MA, United States) and unbound material was filter-washed from the wells by rinsing 3 times with wash buffer. The plate was hybridized with 100 µL/well of bDNA amplifier in Amplifier Diluent (Panomics, CA, United States) at 54 °C for 1 h. After the plate was filter- washed twice with wash buffer and incubated at 50 °C for 1 h with 100 µL/well of 5’-dT(Biotin)-conjugated label probe (Panomics, CA, United States) diluted in Label Probe Diluent (Panomics, CA, United States). After 2 washes, streptavidin-conjugated R-phycoerythrin diluted in SA-PE diluent (20 mmol/L Tris-HCl, 400 mmol/L lithium chloride, 1 mL/L Tween 20, 1 mL/L bovine serum albumin, and 5 mL/L Micr-O-protect) was added and the plate was shaken and incubated at room temperature for 30 min. We washed the beads to remove unbound SA-PE and then evaluated them with Bio-Plex® 200 system (Bio-Rad, MA, United States). The SA-PE fluorescence measured from each bead was proportional to the number of mRNA transcripts captured by the beads. Expression of target-specific RNA molecules was calculated as the mean values from triplicate cultures and normalized against Actin gene (high expression housekeeping gene).

Polymorphism analysis

A standard non-enzymatic method, using the QIA-AMP® DNA Blood Maxi Kit (Qiagen GmbH, Hilden, Germany) was used to extract Genomic DNA from peripheral blood leucocytes of all CD patients and healthy controls. In addition, DNA samples from 70 healthy Caucasian subjects (140 alleles) were analysed as controls. Three exon of the CARD15/NOD2 gene (Exon 4, Exon 8, Exon 11), were amplified by PCR using pairs of primers derived from the published sequence of the gene (available upon request). Each exon is associated with the three main single-nucleotide polymorphisms (SNPs) (R702W-C2104T; G908R-G2722C; 1007fs-3020insC). These three main variants, associated with susceptibility to CD, represented 32%, 18%, and 31%, respectively, of the total CD mutations[13-15].

The BigDye® Terminator Cycle Sequencing kit (Applied Biosystems, CA, United States) was used to perform direct sequencing of PCR amplified products (SNPs rs87950, rs127951, and rs137955) of the CARD15/NOD2 gene. The samples were analysed in an ABI Prism® 310 genetic analyzer (Applied Biosystems, CA, United States). The of the sequences were confirmed with the analysis of newly-amplified fragments and the sequencing of both DNA strands.

Statistical analysis

SSPS software vers. 10 (SPSS Inc., IL, United States) was used to perform the statistical analysis. All comparisons of genes mRNA expression in tissues (non-inflamed and inflamed areas) were performed by non-parametric assay (Mann-Whitney test, Wilcoxon test). Data are reported as mean and ranges unless otherwise stated. A P-value < 0.05 was accepted as statistically significant. Furthermore, to better characterize the different clinical CD phenotypes, we compared the results regarding the CARD15, CCR6, interferon gamma, and IL-17A genes to colonic CD patients previously examined for these same genes.

Histological analysis

Once removed, tissue samples were rinsed in 0.1 M, pH 7.0 cacodylate buffer, the same used in prefixation and further steps of histological preparation. Samples were then placed in Karnovsky (1965)[16], aldehyde solution, and after 3 h prefixation (4°C), underwent prolonged washing in the buffer. Surgery specimens were reduced into approximately 20 mm3 fragments that were post-fixed (1 h 30 min, 4°C) with 1% OsO4 in cacodylate. These specimens were washed in the buffer, dehydrated in graded ethanol series, soaked in propylene oxide, and embedded in Epon 812. Flat blocks were obtained after polymerization, which were reduced into semi-thin sections (1.5 µm thick), using an 8800 ULTROTOME III LKB equipped with glass knives. Semi-thin sections were stained with borax buffered 1% toluidine blue, and observed with a LEITZ DMRB, in order to collect LM digital images (JPG) for structural analysis. Subsequent ultrastructural observations were carried out on ultrathin sections, obtained with an ULTROTOME NOVA LKB, using a DIATOME diamond knife. Ultrathin sections with gold yellow to silver gray interference colour were selected and collected on uncoated 200-300 mesh copper grids to be electron-dense stained with a hydroalcoholic saturated solution (25 mg/mL) of uranyl acetate, followed by alkaline lead citrate (2 mg/mL). These sections where finally observed (80 KV) with a PHILIPS 201 TEM (BIO, UNIFI), and analogic images were collected, which were later acquired and stored as digital TIFF files using a DIMAGE SCAN DUAL (MINOLTA).

RESULTS

Expression of CD susceptibility genes in the inflamed ileum tissue

The simultaneous expression of 24 genes involved in the pathogenesis of CD was studied in surgical specimens from 14 CD patients with ileal localization of disease. The expression of genes in inflamed ileal mucosa was compared to that of non-inflamed ileal sites collected from the same patient. We observed a significant increase in mRNA levels of twelve genes compared to internal control (Figure 1).

Figure 1.

Figure 1

Quantitative evaluation of gene expression using multiplex gene assay in surgical ileum specimens of CD patients. The abscissa shows the genes evaluated in inflamed and not inflamed tissue; the axis of the ordinates shows the value of expression of the gene normalized to the housekeeping actin (gene/β actin ratio). The first seven genes are more closely related to immunity. P value is reported only when statistically significant (P < 0.05).

Figure 1 shows that genes related to innate immune response (NOD 2, ATG16L1, DEFB4), and to adaptive immune response (CCR6, IL17A, IL17F, IL23R, IFN-γ) were significantly increased in inflamed mucosa of CD patients compared with non-inflamed sites. Moreover, the levels of mRNA for genes involved in physiological functions of epithelial cells, such as JAK2, TNFSF15, and SLC22A4 were higher in inflamed mucosa compared to non-inflamed mucosa and the differences in expression reached statistical significance.

Detection of CARD15 polymorphism

DNA samples obtained from peripheral blood were sequenced to investigate the presence of polymorphisms of CARD15/NOD2 gene. The results of this analysis showed that four patients (28.5%) included in this study are carriers of at least one of the polymorphisms investigated, suggesting that genetic factors might contribute to the dysregulated expression of CARD15/NOD2 gene[17-19].

Morphological analysis

In order to observe the morphology of inflamed tissue samples, light microscopy (LM) and TEM micrographs were obtained. Both gut wall and Lieberkühn crypts retain usual features in both lining epithelium and lamina propria. Epithelial cells consist of constitutive enterocytes along with goblet mucocytes, whereas the underlying connective tissue contains large amounts of cells with wide morphological variety (Figure 2). Goblet cells are involved in impressive secretory processes, releasing a moderately opaque product into cryptal and gut lumen through gaps between enterocytes apices (Figure 3). As a consistent pattern, the lamina propria contains granulocytes and plasma cells.

Figure 2.

Figure 2

Representative Light microscope (LM) of the lamina propria between Lieberkühn crypts in inflamed ileal tissue of CD patient number 7b. Notice muciparous goblet cells in cryptal epithelium and large amount and variety of immune cells (arrows) in the connective tissue. Semithin (1 µm thick) section, toluidine blue staining; cc = goblet cell, ec = enterocyte. Scale bar (4 cm) = 70 µm.

Figure 3.

Figure 3

Representative TEM micrograph of Lieberkühn crypt wall and lumen that contains mucous product released (large arrows) by goblet cells (CC) in inflamed ileal tissue CD patient number 7b. Small arrows indicate transport processes involving apical and lateral surfaces of enterocytes. Scale bar (1 cm) = 1 µm.

DISCUSSION

Among the numerous genes that have been studied so far with respect to CD, strong and replicated associations have been identified with NOD2, IL23R, and ATG16L1 genes[20]. Environmental factors like smoking, low-fiber and, high-carbohydrate diet, altered GM, and medications such as non-steroidal anti-inflammatory drugs interact with genetic background and induce abnormal inflammation and dysregulation of the immune response. Clinical symptomatology relates to such dysregulation.

The clinical course of CD is conditioned by several parameters such as disease location, extra-intestinal manifestation, and age at onset[21]. Strictures and fistulas are more frequent in patients with ileal disease, whereas Crohn's colitis remains uncomplicated for many years. On the whole, almost 80% of patients with CD require intestinal surgery, with a permanent stoma required by almost 10%. The presence of selected mutations in the NOD2 gene (see, e.g., 605956.0001-605956.0003) (IBD1; 266600) has been associated with susceptibility to ileum-localized CD[22]; patients homozygous for the 1007fs mutation had an early disease onset with long-segment ileal stenoses and entero-enteral fistulas; they frequently needed surgical intervention and had a high risk of recurrence[23,24]. Beside NOD2 gene, huge genome-wide linkage-analyses and meta-analyses have described several CD susceptibility regions including IBD5 locus, DLG5, and autophagy- related 16-like 1 (ATG16L1) gene, JAK2, STAT3 interleukin-23 receptor (IL23R), SLC22A4 and SLC22A5 TNFSF15[14].

In this paper, we evaluated the expression of 24 genes that were associated to CD susceptibility[10]. mRNA was extracted from gut specimens obtained from patients with CD ileal localization of CD, undergoing surgery. We used a multiplex gene assay which directly quantifies the mRNA amounts without need of reverse transcription and gives a detailed picture of the inflammation process for each patient[11]. The same technique was used to quantify gene expression in colonic mucosa from surgical specimens or endoscopic bioptic fragments obtained by CD patients with predominant colonic (L2) location[10].

The analysis revealed a clear activation of immune-adaptive Th17 response in association with a Th1 response in inflamed mucosa of patients undergoing surgery suggesting a dysregulated and very aggressive immune-inflammatory response.

Here gene expression analysis of inflamed ileal mucosa revealed an increased expression of genes involved in adaptive immune response compared to non-inflamed tissue. In particular, we found a significant increase of IL17A and IL17F, IL 23R and CCR6 gene expression suggesting an activation of a Th17 adaptive response[25,26] similar to that found in gut mucosa of patients with colonic localization. According with this hypothesis, three additional genes involved in Th17 differentiation as JAK2, STAT3 and TNFSF15[27,28] were found to be overexpressed in inflamed ileal mucosa of CD patients compared to non- inflamed sites. Furthermore, as we expected, the expression of the antimicrobial peptides as defensin (DEFB4)[29] and Hepcidin 6 (HAMP)[30] were significantly increased in inflamed mucosa of CD patients compared with non-inflamed sites, suggesting the overwhelming stimulation of epithelial cells by commensal GM. Indeed, while the human β-defensin (HBD) 1 is constitutively expressed, other genes, like HBD2 (gene name DEFB4), show pathogen and/or inflammation dependent upregulation[31] while also being inducible by probiotic bacteria[32]. Conversely, HAMP transcription mediates the effects of host defence and inflammation. Shanmugam et al. provided persuasive evidence in support of an important role for the GM composition in influencing hepcidin expression during intestinal inflammation in mouse models of colitis[33].

As the position of the pathogenic tissue may condition not only the clinical course of the disease but also the probability to require surgery, we also compared with the same methodology (Quantigene 2.0) the expression of selected genes (IFN-γ, CCR6, IL17A, NOD2) involved in immune responses in inflamed mucosa with predominant ileal location with the one previously studied[10] in inflamed mucosa with colonic location. mRNA expression for IFN-γ γ and for the chemokine CCR6 appeared significantly higher in ileal site compared to colonic site (ileal CD = 2.7 ± 1.5; colonic CD = 0.2 ± 0.06; P = 0.01). The mRNA for IL-17 and NOD2 appeared to be expressed at higher levels in ileal site compared to colonic site, even if the difference is not statistically significant (P ≥ 0.05). The significant differences in the expression levels of IFN-γ gene (higher expression in specimens from patients with ileal localization compared to patients with colonic localization) may suggest an increased damage of the ileal mucosa due to the simultaneous presence of Th1 and Th17 effector cells and/or the shift of Th17 cells to Th1 effectors functionally more aggressive than Th17 unshifted cells[34,35].

Furthermore, according to a worse clinical course of patient with ileal localization of CD compared with patient with colonic localization[36], the increased expression of IL17 and NOD2 in mucosal fragments from patients with ileal CD compared to patients with colonic CD is in agreement with the NOD2 –dependent regulation of immunity in mouse intestinal tract[37]. We suppose that the above differences between the two gut tracts (ileal and colonic) may be due to the Paneth cells at the bottom of the crypts of Lieberkühn in the small intestine, which produce antimicrobial peptides and hinder commensal GM and pathogenic bacteria to penetrate gut mucosa. Initially described as innate immune cells producing antimicrobial products, Paneth cells have recently been suggested to constitute a cardinal component of the intestinal stem cell niche. In fact, Paneth cells contribute to controlling the luminal flora as well as repairing the intestinal barrier following an insult. Genomic alterations that impede the Paneth cell compartment functionality can potentially increase the propensity to develop CD[38].

As a consistent trait, cryptal globlet cells produce large amounts of mucus that performs the double role of barrier and holder of antimicrobial products. The microscopic anatomy analysis aims to provide some details that illustrate phenotypic features: the large cell variety in the lamina propria includes immune lines that represent a further defense tool. Although these morphological traits are not directly related to specific gene outputs, they illustrate the tissue responses to key gene deregulation.

As a pilot study, our study presents a low number of subjects investigated which may have influenced the statistical power of the results. To confirm these results, studies with a larger number of patients are needed. In addition, gene expression was evaluated with Multiplex Gene Assay only. This method directly quantifies the mRNA amounts without need of reverse transcription and gives a detailed picture of the metabolic processes for each patient but it should be validated by comparisons with additional techniques to evaluate gene expression.

One of the main purposes of our research is therefore to identify new molecules involved in metabolic pathways that could potentially represent new biological drugs to identify the appropriate therapy in relation to the clinical phenotype of the CD patient.

ARTICLE HIGHLIGHTS

Research background

The interplay of environmental, genetic and microbial elements influences the etiopathogenesis of Crohn’s disease (CD). Differences in the clinical course of CD have recently been reported in patients with ileal or colonic localization of the inflammatory process.

Research motivation

Aim of this study was to define biochemical and histological differences in intestinal biopsies from patients with ileal or colonic localization of Crohn disease in order to identify new assays which can be useful for planning individual therapeutic strategies

Research objectives

Main objective of the current research was to investigate the expression of genes involved in immune-inflammatory pathways in gut mucosa from patients with ileal or colonic localization of CD and to correlate the results of gene expression with those obtained through a classical morphological analysis of surgical biopsies.

Research methods

A Multiplex Gene Assay was used to assess the simultaneous expression of 24 genes related to immune-inflammatory process and to CD pathogenesis. Structural and ultrastructural features of gut samples were also evaluated through Light microscopy (LM) and Transmission Electron Microscopy (TEM) techniques.

Research results

We observed a strong activation of genes involved in TH-1- and TH-17 immune response in patients with ileal localization of CD compared to patients with colonic localization. In addition, the expression of genes for antimicrobial peptides as DEFB4 and HAMP was found highly stimulated in ileal mucosa from CD patients suggesting a possible interference with microbial commensals at this site.

Research conclusions

Our results indicate that patients with ileal localization of CD have a stronger activation of TH-1 and TH-17 immune-inflammatory responses compared with patients with colonic localization of the disease thus defining a clear subclinical phenotype of CD.

Research perspectives

These results may suggest that therapeutic strategies with biological drugs in CD patients can be differentiated depending on the location of the disease

ACKNOWLEDGEMENTS

We would like to thank Dr. Michele Tanturli for the statistical support, Dr. Giulia Ricciardi for additional manuscript revision, and all the patients who participated to this study,

Footnotes

Institutional review board statement: The study was reviewed and approved by EC of AOUC of Florence on May 2nd, 2011, No. 2011/0018055 rif.95/10, authorization Gen Dir 17/572011 No. 2011/0018055.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare that they have no competing interests.

Data sharing statement: No additional data are available.

STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

Manuscript source: Invited manuscript

Peer-review started: March 20, 2019

First decision: May 9, 2019

Article in press: July 27, 2019

Specialty type: Medicine, Research and Experimental

Country of origin: Italy

Peer-review report classification

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: El-Hussuna A, Mattar MC, Christodoulou DK, Day AS S-Editor: Dou Y L-Editor: AE-Editor: Zhou BX

Contributor Information

Francesco Giudici, Marie- Pierre Piccinni, Department of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy.

Letizia Lombardelli, Marie- Pierre Piccinni, Department of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy.

Edda Russo, Marie- Pierre Piccinni, Department of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy. edda.russo@unifi.it.

Tiziana Cavalli, Dipartimento Chirurgico Ortopedico, Ospedale Carlo Poma di Mantova, Firenze 50134, Italy.

Daniela Zambonin, Marie- Pierre Piccinni, Department of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy.

Federica Logiodice, Marie- Pierre Piccinni, Department of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy.

Ornela Kullolli, Marie- Pierre Piccinni, Department of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy.

Lamberto Giusti, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Firenze, Firenze 50134, Italy.

Tatiana Bargellini, Surgical Unit, Department of Surgery and Translational Medicine, University of Firenze, Firenze 50134, Italy.

Marilena Fazi, Surgical Unit, Department of Surgery and Translational Medicine, University of Firenze, Firenze 50134, Italy.

Livia Biancone, Department of Internal Medicine, University of Roma Tor Vergata, Roma 00133, Italy.

Stefano Scaringi, Surgical Unit, Department of Surgery and Translational Medicine, University of Firenze, Firenze 50134, Italy.

Ann Maria Clemente, Marie- Pierre Piccinni, Department of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy.

Eloisa Perissi, Marie- Pierre Piccinni, Department of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy.

Giovanni Delfino, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Firenze, Firenze 50134, Italy.

Maria G Torcia, Marie- Pierre Piccinni, Department of Experimental and Clinical Medicine, University of Firenze, Firenze 50134, Italy.

Ferdinando Ficari, Surgical Unit, Department of Surgery and Translational Medicine, University of Firenze, Firenze 50134, Italy.

Francesco Tonelli, Surgical Unit, Department of Surgery and Translational Medicine, University of Firenze, Firenze 50134, Italy.

Cecilia Malentacchi, Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Firenze, Firenze 50134, Italy.

References

  • 1.Boyapati R, Satsangi J, Ho GT. Pathogenesis of Crohn's disease. F1000Prime Rep. 2015;7:44. doi: 10.12703/P7-44. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Ramos GP, Papadakis KA. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019;94:155–165. doi: 10.1016/j.mayocp.2018.09.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Abegunde AT, Muhammad BH, Bhatti O, Ali T. Environmental risk factors for inflammatory bowel diseases: Evidence based literature review. World J Gastroenterol. 2016;22:6296–6317. doi: 10.3748/wjg.v22.i27.6296. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Li N, Shi RH. Updated review on immune factors in pathogenesis of Crohn's disease. World J Gastroenterol. 2018;24:15–22. doi: 10.3748/wjg.v24.i1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Weiser M, Simon JM, Kochar B, Tovar A, Israel JW, Robinson A, Gipson GR, Schaner MS, Herfarth HH, Sartor RB, McGovern DPB, Rahbar R, Sadiq TS, Koruda MJ, Furey TS, Sheikh SZ. Molecular classification of Crohn's disease reveals two clinically relevant subtypes. Gut. 2018;67:36–42. doi: 10.1136/gutjnl-2016-312518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Russo E, Taddei A, Ringressi MN, Ricci F, Amedei A. The interplay between the microbiome and the adaptive immune response in cancer development. Therap Adv Gastroenterol. 2016;9:594–605. doi: 10.1177/1756283X16635082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577–594. doi: 10.1053/j.gastro.2007.11.059. [DOI] [PubMed] [Google Scholar]
  • 8.Sepehri S, Kotlowski R, Bernstein CN, Krause DO. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:675–683. doi: 10.1002/ibd.20101. [DOI] [PubMed] [Google Scholar]
  • 9.Villmones HC, Haug ES, Ulvestad E, Grude N, Stenstad T, Halland A, Kommedal Ø. Species Level Description of the Human Ileal Bacterial Microbiota. Sci Rep. 2018;8:4736. doi: 10.1038/s41598-018-23198-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Russo E, Lombardelli L, Giudici F, Cavalli T, Ficari F, Fazi M, Scaringi S, Biancone L, Logiodice F, Nesi M, Latiano A, Annese V, Torcia MG, Bechi P, Tonelli F, Piccinni MP, Malentacchi C. Crohn's Colitis: Development of a multiplex gene expression assay comparing mRNA levels of susceptibility genes. Clin Res Hepatol Gastroenterol. 2017;41:435–444. doi: 10.1016/j.clinre.2017.02.004. [DOI] [PubMed] [Google Scholar]
  • 11.Piccinni MP, Lombardelli L, Logiodice F, Tesi D, Kullolli O, Biagiotti R, Giudizi M, Romagnani S, Maggi E, Ficarra G. Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus. Oral Dis. 2014;20:212–218. doi: 10.1111/odi.12094. [DOI] [PubMed] [Google Scholar]
  • 12.Palmieri O, Bossa F, Valvano MR, Corritore G, Latiano T, Martino G, D'Incà R, Cucchiara S, Pastore M, D'Altilia M, Scimeca D, Biscaglia G, Andriulli A, Latiano A. Crohn's Disease Localization Displays Different Predisposing Genetic Variants. PLoS One. 2017;12:e0168821. doi: 10.1371/journal.pone.0168821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Barreiro-de Acosta M, Peña AS. Clinical applications of NOD2/CARD15 mutations in Crohn's disease. Acta Gastroenterol Latinoam. 2007;37:49–54. [PubMed] [Google Scholar]
  • 14.Huang H, Fang M, Jostins L, Umićević Mirkov M, Boucher G, Anderson CA, Andersen V, Cleynen I, Cortes A, Crins F, D'Amato M, Deffontaine V, Dmitrieva J, Docampo E, Elansary M, Farh KK, Franke A, Gori AS, Goyette P, Halfvarson J, Haritunians T, Knight J, Lawrance IC, Lees CW, Louis E, Mariman R, Meuwissen T, Mni M, Momozawa Y, Parkes M, Spain SL, Théâtre E, Trynka G, Satsangi J, van Sommeren S, Vermeire S, Xavier RJ International Inflammatory Bowel Disease Genetics Consortium, Weersma RK, Duerr RH, Mathew CG, Rioux JD, McGovern DPB, Cho JH, Georges M, Daly MJ, Barrett JC. Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature. 2017;547:173–178. doi: 10.1038/nature22969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Keh C, Shatari T, Yamamoto T, Menon A, Clark MA, Keighley MR. Jejunal Crohn's disease is associated with a higher postoperative recurrence rate than ileocaecal Crohn's disease. Colorectal Dis. 2005;7:366–368. doi: 10.1111/j.1463-1318.2005.00766.x. [DOI] [PubMed] [Google Scholar]
  • 16.Karnovsky MJ. A formaldehyde-glutaraldehyde fixative of high osmolarity for use in electron microscopy. J Cell Biol. 1965;27:137A. [Google Scholar]
  • 17.Seiderer J, Schnitzler F, Brand S, Staudinger T, Pfennig S, Herrmann K, Hofbauer K, Dambacher J, Tillack C, Sackmann M, Göke B, Lohse P, Ochsenkühn T. Homozygosity for the CARD15 frameshift mutation 1007fs is predictive of early onset of Crohn's disease with ileal stenosis, entero-enteral fistulas, and frequent need for surgical intervention with high risk of re-stenosis. Scand J Gastroenterol. 2006;41:1421–1432. doi: 10.1080/00365520600703900. [DOI] [PubMed] [Google Scholar]
  • 18.Sidiq T, Yoshihama S, Downs I, Kobayashi KS. Nod2: A Critical Regulator of Ileal Microbiota and Crohn's Disease. Front Immunol. 2016;7:367. doi: 10.3389/fimmu.2016.00367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cucchiara S, Latiano A, Palmieri O, Staiano AM, D'Incà R, Guariso G, Vieni G, Rutigliano V, Borrelli O, Valvano MR, Annese V. Role of CARD15, DLG5 and OCTN genes polymorphisms in children with inflammatory bowel diseases. World J Gastroenterol. 2007;13:1221–1229. doi: 10.3748/wjg.v13.i8.1221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Naser SA, Arce M, Khaja A, Fernandez M, Naser N, Elwasila S, Thanigachalam S. Role of ATG16L, NOD2 and IL23R in Crohn's disease pathogenesis. World J Gastroenterol. 2012;18:412–424. doi: 10.3748/wjg.v18.i5.412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Lazarev M, Huang C, Bitton A, Cho JH, Duerr RH, McGovern DP, Proctor DD, Regueiro M, Rioux JD, Schumm PP, Taylor KD, Silverberg MS, Steinhart AH, Hutfless S, Brant SR. Relationship between proximal Crohn's disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics Consortium. Am J Gastroenterol. 2013;108:106–112. doi: 10.1038/ajg.2012.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Noble CL, Abbas AR, Lees CW, Cornelius J, Toy K, Modrusan Z, Clark HF, Arnott ID, Penman ID, Satsangi J, Diehl L. Characterization of intestinal gene expression profiles in Crohn's disease by genome-wide microarray analysis. Inflamm Bowel Dis. 2010;16:1717–1728. doi: 10.1002/ibd.21263. [DOI] [PubMed] [Google Scholar]
  • 23.Quezada SM, Steinberger EK, Cross RK. Association of age at diagnosis and Crohn's disease phenotype. Age Ageing. 2013;42:102–106. doi: 10.1093/ageing/afs107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Sehgal R, Berg A, Hegarty JP, Kelly AA, Lin Z, Poritz LS, Koltun WA. NOD2/CARD15 mutations correlate with severe pouchitis after ileal pouch-anal anastomosis. Dis Colon Rectum. 2010;53:1487–1494. doi: 10.1007/DCR.0b013e3181f22635. [DOI] [PubMed] [Google Scholar]
  • 25.Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziato F. Th17 and non-classic Th1 cells in chronic inflammatory disorders: two sides of the same coin. Int Arch Allergy Immunol. 2014;164:171–177. doi: 10.1159/000363502. [DOI] [PubMed] [Google Scholar]
  • 26.Pelletier M, Maggi L, Micheletti A, Lazzeri E, Tamassia N, Costantini C, Cosmi L, Lunardi C, Annunziato F, Romagnani S, Cassatella MA. Evidence for a cross-talk between human neutrophils and Th17 cells. Blood. 2010;115:335–343. doi: 10.1182/blood-2009-04-216085. [DOI] [PubMed] [Google Scholar]
  • 27.Floss DM, Klöcker T, Schröder J, Lamertz L, Mrotzek S, Strobl B, Hermanns H, Scheller J. Defining the functional binding sites of interleukin 12 receptor β1 and interleukin 23 receptor to Janus kinases. Mol Biol Cell. 2016;27:2301–2316. doi: 10.1091/mbc.E14-12-1645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. Annu Rev Genomics Hum Genet. 2009;10:89–116. doi: 10.1146/annurev-genom-082908-150013. [DOI] [PubMed] [Google Scholar]
  • 29.Wehkamp J, Koslowski M, Wang G, Stange EF. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease. Mucosal Immunol. 2008;1 Suppl 1:S67–S74. doi: 10.1038/mi.2008.48. [DOI] [PubMed] [Google Scholar]
  • 30.Arnold J, Sangwaiya A, Bhatkal B, Geoghegan F, Busbridge M. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis. Eur J Gastroenterol Hepatol. 2009;21:425–429. doi: 10.1097/MEG.0b013e32830e2885. [DOI] [PubMed] [Google Scholar]
  • 31.Zilbauer M, Dorrell N, Boughan PK, Harris A, Wren BW, Klein NJ, Bajaj-Elliott M. Intestinal innate immunity to Campylobacter jejuni results in induction of bactericidal human beta-defensins 2 and 3. Infect Immun. 2005;73:7281–7289. doi: 10.1128/IAI.73.11.7281-7289.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Schlee M, Harder J, Köten B, Stange EF, Wehkamp J, Fellermann K. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol. 2008;151:528–535. doi: 10.1111/j.1365-2249.2007.03587.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Shanmugam NK, Trebicka E, Fu LL, Shi HN, Cherayil BJ. Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota. J Immunol. 2014;193:1398–1407. doi: 10.4049/jimmunol.1400278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Annunziato F, Romagnani S. The transient nature of the Th17 phenotype. Eur J Immunol. 2010;40:3312–3316. doi: 10.1002/eji.201041145. [DOI] [PubMed] [Google Scholar]
  • 35.Jeschke JC, Mayne CG, Ziegelbauer J, DeCiantis CL, Singh S, Kumar SN, Suchi M, Iwakura Y, Drobyski WR, Salzman NH, Williams CB. A model of TH17-associated ileal hyperplasia that requires both IL-17A and IFNγ to generate self-tolerance and prevent colitis. Mucosal Immunol. 2018;11:1127–1137. doi: 10.1038/s41385-018-0023-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Hovde Ø, Moum BA. Epidemiology and clinical course of Crohn's disease: results from observational studies. World J Gastroenterol. 2012;18:1723–1731. doi: 10.3748/wjg.v18.i15.1723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Kobayashi KS, Chamaillard M, Ogura Y, Henegariu O, Inohara N, Nuñez G, Flavell RA. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science. 2005;307:731–734. doi: 10.1126/science.1104911. [DOI] [PubMed] [Google Scholar]
  • 38.Roda G, Sartini A, Zambon E, Calafiore A, Marocchi M, Caponi A, Belluzzi A, Roda E. Intestinal epithelial cells in inflammatory bowel diseases. World J Gastroenterol. 2010;16:4264–4271. doi: 10.3748/wjg.v16.i34.4264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Fedrigo O, Warner LR, Pfefferle AD, Babbitt CC, Cruz-Gordillo P, Wray GA. A pipeline to determine RT-QPCR control genes for evolutionary studies: application to primate gene expression across multiple tissues. PLoS One. 2010:5. doi: 10.1371/journal.pone.0012545. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034. doi: 10.1186/gb-2002-3-7-research0034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Benyamin B, Esko T, Ried JS, Radhakrishnan A, Vermeulen SH, Traglia M, Gögele M, Anderson D, Broer L, Podmore C, Luan J, Kutalik Z, Sanna S, van der Meer P, Tanaka T, Wang F, Westra HJ, Franke L, Mihailov E, Milani L, Hälldin J, Winkelmann J, Meitinger T, Thiery J, Peters A, Waldenberger M, Rendon A, Jolley J, Sambrook J, Kiemeney LA, Sweep FC, Sala CF, Schwienbacher C, Pichler I, Hui J, Demirkan A, Isaacs A, Amin N, Steri M, Waeber G, Verweij N, Powell JE, Nyholt DR, Heath AC, Madden PAF, Visscher PM, Wright MJ, Montgomery GW, Martin NG, Hernandez D, Bandinelli S, van der Harst P, Uda M, Vollenweider P, Scott RA, Langenberg C, Wareham NJ, van Duijn C, Beilby J, Pramstaller PP, Hicks AA, Ouwehand WH, Oexle K, Gieger C, Metspalu A, Camaschella C, Toniolo D, Swinkels DW, Whitfield JB. Corrigendum: Novel loci affecting iron homeostasis and their effects in individuals at risk for hemochromatosis. Nat Commun. 2015;6:6542. doi: 10.1038/ncomms7542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003;73:1282–1292. doi: 10.1086/379927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, Newman B, Van Oene M, Cescon D, Greenberg G, Griffiths AM, St George-Hyslop PH, Siminovitch KA. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 2004;36:471–475. doi: 10.1038/ng1339. [DOI] [PubMed] [Google Scholar]
  • 44.Girardin M, Dionne S, Goyette P, Rioux J, Bitton A, Elimrani I, Charlebois P, Qureshi I, Levy E, Seidman EG. Expression and functional analysis of intestinal organic cation/L-carnitine transporter (OCTN) in Crohn's disease. J Crohns Colitis. 2012;6:189–197. doi: 10.1016/j.crohns.2011.08.003. [DOI] [PubMed] [Google Scholar]
  • 45.Fransen K, van Sommeren S, Westra HJ, Veenstra M, Lamberts LE, Modderman R, Dijkstra G, Fu J, Wijmenga C, Franke L, Weersma RK, van Diemen CC. Correlation of genetic risk and messenger RNA expression in a Th17/IL23 pathway analysis in inflammatory bowel disease. Inflamm Bowel Dis. 2014;20:777–782. doi: 10.1097/MIB.0000000000000013. [DOI] [PubMed] [Google Scholar]
  • 46.Ueno A, Ghosh A, Hung D, Li J, Jijon H. Th17 plasticity and its changes associated with inflammatory bowel disease. World J Gastroenterol. 2015;21:12283–12295. doi: 10.3748/wjg.v21.i43.12283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Nguyen PM, Putoczki TL, Ernst M. STAT3-Activating Cytokines: A Therapeutic Opportunity for Inflammatory Bowel Disease? J Interferon Cytokine Res. 2015;35:340–350. doi: 10.1089/jir.2014.0225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N, Caillat-Zucman S, Paul P, Gornet JM, Douay C, Ravet S, Tamouza R, Charron D, Lémann M, Mayer L, Toubert A. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology. 2007;132:2346–2358. doi: 10.1053/j.gastro.2007.03.025. [DOI] [PubMed] [Google Scholar]
  • 49.Muro M, López-Hernández R, Mrowiec A. Immunogenetic biomarkers in inflammatory bowel diseases: role of the IBD3 region. World J Gastroenterol. 2014;20:15037–15048. doi: 10.3748/wjg.v20.i41.15037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Santarlasci V, Cosmi L, Maggi L, Liotta F, Annunziato F. IL-1 and T Helper Immune Responses. Front Immunol. 2013;4:182. doi: 10.3389/fimmu.2013.00182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Danese S, Grisham M, Hodge J, Telliez JB. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155–G162. doi: 10.1152/ajpgi.00311.2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Tuller T, Atar S, Ruppin E, Gurevich M, Achiron A. Common and specific signatures of gene expression and protein-protein interactions in autoimmune diseases. Genes Immun. 2013;14:67–82. doi: 10.1038/gene.2012.55. [DOI] [PubMed] [Google Scholar]
  • 53.Koczulla AR, Bals R. Antimicrobial peptides: current status and therapeutic potential. Drugs. 2003;63:389–406. doi: 10.2165/00003495-200363040-00005. [DOI] [PubMed] [Google Scholar]
  • 54.Hugot JP. CARD15/NOD2 mutations in Crohn's disease. Ann N Y Acad Sci. 2006;1072:9–18. doi: 10.1196/annals.1326.011. [DOI] [PubMed] [Google Scholar]
  • 55.Wehkamp J, Stange EF, Fellermann K. Defensin-immunology in inflammatory bowel disease. Gastroenterol Clin Biol. 2009;33 Suppl 3:S137–S144. doi: 10.1016/S0399-8320(09)73149-5. [DOI] [PubMed] [Google Scholar]
  • 56.Gersemann M, Becker S, Kübler I, Koslowski M, Wang G, Herrlinger KR, Griger J, Fritz P, Fellermann K, Schwab M, Wehkamp J, Stange EF. Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation. 2009;77:84–94. doi: 10.1016/j.diff.2008.09.008. [DOI] [PubMed] [Google Scholar]
  • 57.Verga Falzacappa MV, Muckenthaler MU. Hepcidin: iron-hormone and anti-microbial peptide. Gene. 2005;364:37–44. doi: 10.1016/j.gene.2005.07.020. [DOI] [PubMed] [Google Scholar]
  • 58.Mleczko-Sanecka K, Casanovas G, Ragab A, Breitkopf K, Müller A, Boutros M, Dooley S, Hentze MW, Muckenthaler MU. SMAD7 controls iron metabolism as a potent inhibitor of hepcidin expression. Blood. 2010;115:2657–2665. doi: 10.1182/blood-2009-09-238105. [DOI] [PubMed] [Google Scholar]
  • 59.Gardet A, Benita Y, Li C, Sands BE, Ballester I, Stevens C, Korzenik JR, Rioux JD, Daly MJ, Xavier RJ, Podolsky DK. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol. 2010;185:5577–5585. doi: 10.4049/jimmunol.1000548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Schapansky J, Nardozzi JD, Felizia F, LaVoie MJ. Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy. Hum Mol Genet. 2014;23:4201–4214. doi: 10.1093/hmg/ddu138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Bamias G, Martin C, 3rd, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Friel CM, Mize J, Bickston SJ, Pizarro TT, Wei P, Cominelli F. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003;171:4868–4874. doi: 10.4049/jimmunol.171.9.4868. [DOI] [PubMed] [Google Scholar]
  • 62.Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, Ding J, Li Y, Tejasvi T, Gudjonsson JE, Kang HM, Allen MH, McManus R, Novelli G, Samuelsson L, Schalkwijk J, Ståhle M, Burden AD, Smith CH, Cork MJ, Estivill X, Bowcock AM, Krueger GG, Weger W, Worthington J, Tazi-Ahnini R, Nestle FO, Hayday A, Hoffmann P, Winkelmann J, Wijmenga C, Langford C, Edkins S, Andrews R, Blackburn H, Strange A, Band G, Pearson RD, Vukcevic D, Spencer CC, Deloukas P, Mrowietz U, Schreiber S, Weidinger S, Koks S, Kingo K, Esko T, Metspalu A, Lim HW, Voorhees JJ, Weichenthal M, Wichmann HE, Chandran V, Rosen CF, Rahman P, Gladman DD, Griffiths CE, Reis A, Kere J Collaborative Association Study of Psoriasis (CASP); Genetic Analysis of Psoriasis Consortium; Psoriasis Association Genetics Extension; Wellcome Trust Case Control Consortium 2, Nair RP, Franke A, Barker JN, Abecasis GR, Elder JT, Trembath RC. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44:1341–1348. doi: 10.1038/ng.2467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Bertin J, Wang L, Guo Y, Jacobson MD, Poyet JL, Srinivasula SM, Merriam S, DiStefano PS, Alnemri ES. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J Biol Chem. 2001;276:11877–11882. doi: 10.1074/jbc.M010512200. [DOI] [PubMed] [Google Scholar]
  • 64.Parkes M. Evidence from genetics for a role of autophagy and innate immunity in IBD pathogenesis. Dig Dis. 2012;30:330–333. doi: 10.1159/000338119. [DOI] [PubMed] [Google Scholar]
  • 65.Aguirre JI, Plotkin LI, Gortazar AR, Millan MM, O'Brien CA, Manolagas SC, Bellido T. A novel ligand-independent function of the estrogen receptor is essential for osteocyte and osteoblast mechanotransduction. J Biol Chem. 2007;282:25501–25508. doi: 10.1074/jbc.M702231200. [DOI] [PubMed] [Google Scholar]
  • 66.Cejalvo T, Sacedón R, Hernández-López C, Diez B, Gutierrez-Frías C, Valencia J, Zapata AG, Varas A, Vicente A. Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development. Immunology. 2007;121:94–104. doi: 10.1111/j.1365-2567.2007.02541.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, Rosenstiel P, Albrecht M, Croucher PJ, Seegert D, Nikolaus S, Hampe J, Lengauer T, Pierrou S, Foelsch UR, Mathew CG, Lagerstrom-Fermer M, Schreiber S. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004;36:476–480. doi: 10.1038/ng1345. [DOI] [PubMed] [Google Scholar]

Articles from World Journal of Clinical Cases are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES